# Avelumab plus axitinib for translocation renal cell carcinoma: A case series and literature review

## TL;DR

This paper reports two cases where avelumab plus axitinib treatment showed long-term effectiveness in patients with translocation renal cell carcinoma.

## Contribution

The study presents new clinical evidence supporting avelumab–axitinib as a potential treatment for translocation renal cell carcinoma.

## Key findings

- A 72-year-old woman with tRCC remained progression-free for 90 weeks after avelumab–axitinib treatment.
- A 41-year-old woman with tRCC metastasis remained progression-free for 43 weeks after the same treatment.
- The results suggest a long-term antitumor effect of avelumab–axitinib in some tRCC patients.

## Abstract

Patients with translocation renal cell carcinoma (tRCC) have a poor prognosis without standardized treatment.

The first case was of a 72‐year‐old woman who underwent robot‐assisted partial nephrectomy for a left renal tumor and was pathologically diagnosed with tRCC. Recurrence was observed in the left retroperitoneal soft tissue. After treatment with avelumab–axitinib, continued progression‐free survival was confirmed at the 90‐week follow‐up. The second case was of a 41‐year‐old woman referred to our hospital and presented with translocation renal cell carcinoma metastasis to a para‐aortic lymph node. After treatment with avelumab–axitinib, continued progression‐free survival was confirmed at the 43‐week follow‐up.

The outcomes of these cases indicate that avelumab–axitinib therapy has a long‐term antitumor effect in some patients with tRCC.